Hormone therapy

Hormone therapy has been studied in 146 papers since 2006: 2 trials and 61 observational studies in people, 80 reviews; 56 in the past year. The newest story, Nov 16, 2026: “Menopause stage linked to brain response differences in women”.

Intervention

146 papers study it81 findingsUpdated

Research on it is growing 51% faster than aging research as a whole: 26 papers in the latest year counted

7 new papers in 30 daysSee all 146 papers on hormone therapy

At a glance

Current hormone therapy use is linked with lower mortality in women; reviews describe observational links with lower Alzheimer’s risk across independent labs, alongside studies showing no clear link. A human trial reports fewer menopausal symptoms during late menopausal transition with sleep difficulty; an observational study links therapy with higher venous thromboembolism risk. Some papers declare company ties.

81 findings in 59 papers from 2012 to 2026, 20 of them since April 2026

Independent labs found the same change in people. 39 independent labs in 17 countries.

“In the hormone therapy and combination groups, FSH and LH levels decreased significantly, while E2 levels increased significantly after treatment (p < 0.05)”
A randomized controlled trial on the effect of Gushukang on bone mineral density in perimenopausal and postmenopausal womenGynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology2026doi:10.1080/09513590.2026.2659980

5 of its findings point the other way.

Humans: replicated by independent labs. Cells, worms or flies and mice: nothing yet.
  • 39 independent labs in 17 countries
  • 5 findings against
  • Funders: National Institutes of Health and others
  • 4 of 59 findings with company ties
  • Human trial2
  • Humans61
  • In silico2

What did studies of hormone therapy find?

38

Studies of hormone therapy measured 38 outcomes, among them vasomotor symptoms, bone loss and menopausal symptoms.

Vasomotor symptoms

downin humans2

2 studies
  1. Hormone therapy decreases vasomotor symptoms in humans (menopause).

    “Hormone therapy remains the most effective treatment of vasomotor symptoms and genitourinary syndrome of menopause (GSM)”

    Reviewmenopause

    Hormone Therapy Considerations for Breast Cancer Survivors and High-Risk Women

    Endocrinology and metabolism clinics of North America

  2. Hormone therapy decreases vasomotor symptoms in humans (menopause).

    “Hormone therapy is the most effective treatment of vasomotor symptoms”

    Reviewmenopausefemales

    Menopause

    The Medical clinics of North America

More on Vasomotor symptoms

Bone loss

downin humans2

2 studies
  1. Hormone therapy is linked with less bone loss in women of reproductive age with estrogen deficiency.

    “basic hormone therapy prevents further bone loss”

    Humansin women of reproductive age with estrogen deficiencyfemales

    Treatment of osteoporosis in women with early menopause

    Yakut Medical Journal

  2. Hormone therapy prevents bone loss in humans.

    “has been shown to prevent bone loss and fracture”

    Reviewbonefemales

    Menopause, revisited: Who’s still afraid of hormones?

    British Columbia medical journal

Menopausal symptoms

upin humans1downin humans1

2 studies
  1. Hormone therapy decreases menopausal symptoms in humans (late menopausal transition with sleep difficulty) (Menopause Rating Scale: 29.0 ± 5.2 vs 21.6 ± 3.0; P = 0.009).

    “Total scores of the Insomnia Severity Index and Menopause Rating Scale were better 10 weeks after starting HT”

    Human triallate menopausal transition with sleep difficulty10 weeksfemalesn = 10

    Association of hormone therapy and changes of objective sleep quality in women of late menopausal transition with sleep disorder: a preliminary study

    Menopause (New York, N.Y.)

  2. Hormone therapy improves menopausal symptoms in menopausal women.

    “HT is very effective at treating menopausal symptoms”

    Reviewin menopausal women

    From discovery to debate: The history of menopausal hormone therapy and its impact on cardiovascular health

    Autonomic neuroscience : basic & clinical

Major adverse cardiovascular events

no changein humans1HR 1.11

1 study
  1. Hormone therapy was not clearly linked with major adverse cardiovascular events in humans (Continuation versus discontinuation after first myocardial infarction) (Adjusted HR 1.11, 95% CI 0.79–1.56; p=0.540).

    “Continuation of hormone therapy was not significantly associated with increased risk of MACE compared with discontinuation”

    HumansContinuation versus discontinuation after first myocardial infarctionsystemic1 yearfemalesn = 1,818

    Continuing hormones after heart attack not linked to added 1-year risk

    ESC Congress 2026 abstract

ASCVD risk factors or events

no changein humans1

1 study
  1. Hormone therapy was not clearly linked with ASCVD risk factors or events in humans (Black and Latina transgender women with HIV; association with hormone duration).

    “Neither years since HIV diagnosis nor hormone duration were associated with ASCVD risk factors or events.”

    HumansBlack and Latina transgender women with HIV; association with hormone durationtransgender womensn = 108

    Cross-sectional Comparison of the PREVENT and Pooled Cohort Equations for 10-Year Atherosclerotic Cardiovascular Risk Estimates in a U.S. Cohort of Black and Latina Transgender Women with HIV

    Journal of acquired immune deficiency syndromes (1999)

Hot flushes

downin humans1

1 study
  1. Hormone therapy decreases hot flushes in humans (perimenopausal female misattributing hot flushes to opioid withdrawal).

    “she started hormone therapy, which completely resolved her symptoms.”

    Human trialperimenopausal female misattributing hot flushes to opioid withdrawalfemales

    The Overlapping Symptoms of Perimenopause and Opioid Withdrawal: When Hormone Therapy is "Even more Important for My Recovery than My Methadone"

    Journal of addiction medicine

Mortality

no changein humans1

1 study
  1. Hormone therapy was not clearly linked with mortality in humans (former vs never users).

    “Former users did not differ significantly from never users in risk of death or cardiovascular outcomes.”

    Humansformer vs never users14.4-year follow-upfemalesn = 3,235

    Role of coronary artery calcium in the association between hormone therapy status and incident death and cardiovascular disease: the Multi-Ethnic Study of Atherosclerosis

    Menopause (New York, N.Y.)

Overall skin quality

upin humans1

1 study
  1. Hormone therapy improves overall skin quality in humans (menopause).

    “Hormone therapy showed consistent benefits in improving hydration, elasticity, dermal thickness, barrier function, wound healing, and overall skin quality”

    Reviewmenopause

    Menopause and Skin Aging in Primary Health Care: The Impact of Hormone Therapy on Skin Health and the Role of the Family and Community Doctor

    International Journal of Clinical & Experimental Dermatology

Anxiety

downin humans1

1 study
  1. Hormone therapy decreases anxiety in humans (menopausal women).

    “hormone therapy and phytoestrogens were associated with the alleviation of psychological symptoms in menopausal women, particularly in mood and anxiety.”

    Reviewmenopausal women

    Efficacy of hormone therapy and phytoestrogens on the psychological symptoms of menopausal women: a systematic review, meta-analysis, and trial sequential analysis

    Frontiers in medicine

More on Anxiety

Insulin resistance

downin humans1

1 study
  1. Hormone therapy decreases insulin resistance in humans.

    “regular physical activity, balanced nutrition, and hormone therapy showed positive effects on insulin sensitivity and metabolic control”

    Reviewfemales

    Menopause, Visceral Adiposity, and Insulin Resistance: Pathophysiological Mechanisms and Cardiovascular Implications

    International Journal of Health Science

Estradiol

upin humans1

1 study
  1. Hormone therapy increases estradiol in humans (p < 0.05).

    “while E2 levels increased significantly after treatment (p < 0.05)”

    Human trial6 monthsfemales

    A randomized controlled trial on the effect of Gushukang on bone mineral density in perimenopausal and postmenopausal women

    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology

More on Estradiol

Follicle stimulating hormone

downin humans1

1 study
  1. Hormone therapy decreases follicle stimulating hormone in humans (p < 0.05).

    “In the hormone therapy and combination groups, FSH and LH levels decreased significantly, while E2 levels increased significantly after treatment (p < 0.05)”

    Human trial6 monthsfemales

    A randomized controlled trial on the effect of Gushukang on bone mineral density in perimenopausal and postmenopausal women

    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology

More on Follicle stimulating hormone

Sleepiness

no changein humans1

1 study
  1. Hormone therapy showed no clear effect on sleepiness in humans (late menopausal transition with sleep difficulty) (Epworth Sleepiness Scale: 7.2 ± 1.7 vs 8.6 ± 4.5; P = 0.309).

    “There was no difference in the Epworth Sleepiness Scale before and after HT”

    Human triallate menopausal transition with sleep difficulty10 weeksfemalesn = 10

    Association of hormone therapy and changes of objective sleep quality in women of late menopausal transition with sleep disorder: a preliminary study

    Menopause (New York, N.Y.)

Insomnia severity

downin humans1

1 study
  1. Hormone therapy decreases insomnia severity in humans (late menopausal transition with sleep difficulty) (Insomnia Severity Index: 14.7 ± 3.0 vs 9.1 ± 3.8; P = 0.010).

    “Total scores of the Insomnia Severity Index and Menopause Rating Scale were better 10 weeks after starting HT”

    Human triallate menopausal transition with sleep difficulty10 weeksfemalesn = 10

    Association of hormone therapy and changes of objective sleep quality in women of late menopausal transition with sleep disorder: a preliminary study

    Menopause (New York, N.Y.)

Objective sleep quality

no changein humans1

1 study
  1. Hormone therapy showed no clear effect on objective sleep quality in humans.

    “However, no significant change was found in objective sleep quality after adjustment for multiple comparisons:”

    Human triallate menopausal transition with sleep difficulty; after adjustment for multiple comparisons10 weeksfemalesn = 10

    Association of hormone therapy and changes of objective sleep quality in women of late menopausal transition with sleep disorder: a preliminary study

    Menopause (New York, N.Y.)

All 38

What is hormone therapy linked with?

35

Studies link hormone therapy with 35 measures, most often Alzheimer's disease (4 studies) and cardiovascular disease (2).

Alzheimer's disease

downin humans3mixedin humans1−35%OR 0.43

4 studies
  1. Hormone therapy is associated with Alzheimer's disease in humans (ever use in women with early bilateral oophorectomy) (OR 0.43, 95% CI 0.23–0.82).

    “ever use of HT was associated with decreased odds of AD only for the BO group (OR = 0.43, 95% CI [0.23, 0.82]).”

    Humansever use in women with early bilateral oophorectomyfemales

    Associated risk and resilience factors of Alzheimer's disease in women with early bilateral oophorectomy: Data from the UK Biobank

    Journal of Alzheimer's disease : JAD

  2. Hormone therapy lowers the risk of Alzheimer's disease in humans (initiated within 10 years of menopause) (35%).

    “cognitive decline by 64%, Alzheimer's disease by 35%”

    Reviewinitiated within 10 years of menopause

    Twenty-Three Years from Error to Correction: The Hormone Therapy Catastrophe and the Urgent Case for Regulatory Reform

    Journal of IVF-Worldwide

  3. Hormone therapy is associated with Alzheimer's disease in humans.

    “clinical trials investigating hormone therapy (HT) for AD prevention have yielded mixed results”

    Reviewbrainfemales

    Estrogen, menopause, and Alzheimer's disease: understanding the link to cognitive decline in women

    Frontiers in molecular biosciences

  4. Hormone therapy lowers the risk of Alzheimer's disease in humans (especially in younger postmenopausal women) (8 of 14 observational studies).

    “Among the 14 observational studies, 8 reported an improvement in cognitive function and a decrease in AD risk, especially in younger postmenopausal women.”

    Reviewespecially in younger postmenopausal womenfemales

    Use of Hormone Therapy in Postmenopausal Women with Alzheimer's Disease: A Systematic Review

    Drugs & aging

More on Alzheimer's disease

Cardiovascular disease

mixedin humans1upin reviews1

2 studies
  1. Hormone therapy is associated with cardiovascular disease in humans (timing of initiation).

    “Although HT is very effective at treating menopausal symptoms, the data regarding cardiovascular benefits have been mixed”

    Reviewtiming of initiation

    From discovery to debate: The history of menopausal hormone therapy and its impact on cardiovascular health

    Autonomic neuroscience : basic & clinical

  2. Hormone therapy raises the risk of cardiovascular disease (long-term use).

    “but long-term use increases the risk of cardiovascular diseases and cancer”

    Reviewlong-term use

    "Adipose-derived mesenchymal stem cell therapy for the management of female sexual dysfunction: Literature reviews and study design of a clinical trial"

    Frontiers in cell and developmental biology

More on Cardiovascular disease

HOMA-IR

upin humans1

1 study
  1. Hormone therapy is associated with HOMA-IR in humans (Prostate cancer patients before radiotherapy).

    “Higher HOMA-IR was observed in patients on hormone therapy ( P < 0.001)”

    HumansProstate cancer patients before radiotherapy

    Healthy lifestyle adherence and insulin resistance in prostate cancer patients undergoing radiotherapy: baseline findings from the MicroStyle study

    European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)

More on HOMA-IR

Motor cortical spike-timing-dependent plasticity

upin humans1

1 study
  1. Hormone therapy is associated with motor cortical spike-timing-dependent plasticity in humans (Compared with perimenopausal and postmenopausal participants).

    “Between groups, both PRE and HT exceeded PERI, and HT also exceeded POST;”

    HumansCompared with perimenopausal and postmenopausal participantscombined continuousmotor cortexfemales

    Menopause stage linked to brain response differences in women

    bioRxivPreprint

Advanced cardiovascular-kidney-metabolic syndrome stage prevalence

downin humans1

1 study
  1. Hormone therapy is associated with advanced cardiovascular-kidney-metabolic syndrome stage prevalence in humans (Postmenopausal women; hormone therapy users compared with nonusers across age groups) (Stage 3 prevalence <30% and Stage 4 prevalence <20% among HT users across all age groups).

    “Among HT users, the rise in Stages 3 and 4 was attenuated compared with non-HT users.”

    HumansPostmenopausal women; hormone therapy users compared with nonusers across age groupsfemalesn = 5,720

    Association of Hormone Therapy with Cardiovascular-Kidney-Metabolic Syndrome Stage Prevalence in Postmenopausal Women

    AHA Scientific Sessions 2026 abstract

More on Advanced cardiovascular-kidney-metabolic syndrome stage prevalence

Major adverse cardiovascular events

upin humans1HR 1.25

1 study
  1. Hormone therapy is associated with major adverse cardiovascular events in humans (Continuation versus discontinuation after first myocardial infarction) (Nonsignificant trend: adjusted HR 1.25, 95% CI 0.98–1.59; p=0.07).

    “At 2 years, there were a corresponding trend towards higher risk among continuers that did not reach statistical significance”

    HumansContinuation versus discontinuation after first myocardial infarctionsystemic2 yearsfemalesn = 1,818

    Continuing hormones after heart attack not linked to added 1-year risk

    ESC Congress 2026 abstract

Endometrial polyp

downin humans1

1 study
  1. Hormone therapy is associated with endometrial polyp in humans (current use at hysteroscopy; regimen unavailable) (aOR 0.15, 95% CI 0.06–0.40; p < 0.001).

    “Current HT use was inversely associated with EP (aOR = 0.15, 95% CI 0.06-0.40; p < 0.001), though regimen data were unavailable.”

    Humanscurrent use at hysteroscopy; regimen unavailablefemales

    Progesterone receptor variants and hormone therapy use in postmenopausal endometrial polyps: a case-control study

    Clinics (Sao Paulo, Brazil)

More on Endometrial polyp

Coronary artery disease

mixedin humans1

1 study
  1. Hormone therapy is associated with coronary artery disease in humans across trial and observational populations.

    “estimate the effect of hormone therapy on coronary heart disease across trial and observational populations.”

    Humansacross trial and observational populations

    Efficient transport and generalization of survival treatment effects

    arXivPreprint

More on Coronary artery disease

Open-angle glaucoma

downin humans1

1 study
  1. Hormone therapy is linked with a lower risk of open-angle glaucoma in females, greatest effect in those <45 years.

    “HT use was associated with delayed diagnosis in females, with the greatest effect in those <45 years.”

    Humansin females, greatest effect in those <45 yearsfemales

    Age, sex, and hormone therapy are associated with open-angle glaucoma: a case-only analysis in U.S. veterans

    Canadian journal of ophthalmology. Journal canadien d'ophtalmologie

More on Open-angle glaucoma

Mortality

downin humans1HR 0.7

1 study
  1. Hormone therapy is linked with a lower risk of mortality in humans (current vs never use) (HR 0.70, 95% CI 0.58-0.86).

    “current HT use versus never use was associated with lower risk for all-cause death (hazard ratio [HR]: 0.70, 95% CI: 0.58-0.86)”

    Humanscurrent vs never use14.4-year follow-upfemalesn = 3,235

    Role of coronary artery calcium in the association between hormone therapy status and incident death and cardiovascular disease: the Multi-Ethnic Study of Atherosclerosis

    Menopause (New York, N.Y.)

All 35

What acts on hormone therapy?

1

Studies name Sexual minority orientation as acting on hormone therapy.

Sexual minority orientation

no changein humans1

1 study
  1. sexual minority orientation was not clearly linked with hormone therapy in humans (presenting to tertiary care women's health clinics).

    “The likelihood of being on hormone therapy or selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors was comparable between groups.”

    Humanspresenting to tertiary care women's health clinicsfemalesn = 2,273

    Menopause symptoms and treatment in sexual minority women

    Menopause (New York, N.Y.)

Funding

32 grants since 2016

National Institute on Aging$13.2MVetenskapsrådetSEK 14.3MNational Heart, Lung, and Blood Institute$1.2M

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    A human study links current hormone therapy use to lower mortality in women, but not former use. Another reports lower open-angle glaucoma risk in women; a human trial reports fewer hot flushes, and a human preprint reports coronary heart disease associations.

  2. Summary written from the findings.

Latest

Dec 2025: 2Jan 2026: 5Feb 2026: 6Mar 2026: 4Apr 2026: 3May 2026: 8Jun 2026: 3Jul 2026: 4Aug 2026: 2Sep 2026: 7Oct 2026: 7Nov 2026: 354 papers in 12 months
bioRxiv

Menopause stage linked to brain response differences in women

After stimulation, brain-to-muscle responses rose 48% from baseline before menopause; the 32% rise in hormone therapy users was not statistically significant.After stimulation, brain-to-muscle responses rose 48% from baseline before menopause; the 32% rise in hormone therapy users was not statistically significant.

Preprint: cross-sectional · 46 peopleReproductive system
ESC Congress 2026 Abstract

Continuing hormones after heart attack not linked to added 1-year risk

The adjusted relative event rate was 1.11 for continuing versus stopping hormone therapy at one year; the range of likely values included no difference.The adjusted relative event rate was 1.11 for continuing versus stopping hormone therapy at one year; the range of likely values included no difference.

Cohort · 1,818 peopleMyocardial infarction

See all 146 papers on hormone therapy